Product Launch Tracker: eHCPs are delighted with the approval of Enhertu, for patients with HER2-positive solid tumours.

09.05.2024 | Tracker

Product Launch Tracker: eHCPs are delighted with the approval of Enhertu, for patients with HER2-positive solid tumours.

Throughout April 2024 CREATION.co tracked the global conversations of 1,432 HCPs who posted 2,271 tweets about the launches and approvals of new products.

In April, 196 fewer eHCPs discussed treatment approvals than in March, publishing 6% fewer posts during that time.

On 5 April, the FDA approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for patients with unresectable or metastatic HER2-positive solid tumours. eHCPs were thrilled about this “agonistic”  approval describing it as “unprecedented” and as a “major milestone in precision medicine”. Dr Joaquim Bellmunt, an oncologist in Boston, stated that “this treatment provides a new option for bladder cancer and other tumour types”. 

On 18 April, the FDA approved a new indication for Genentech’s Alecensa (alectinib) for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Most eHCPs were pleased with the approval, calling it “a big deal”. eHCPs such as Dr Rami Manochakian posted enthusiastically about the positive outcomes of the ALINA trial. Dr David Gandara, an oncologist in California, commented that “the advances continue in the oncogene-driven NSCLC space”.

On 22 April, more than 40 eHCPs humorously commented on the particular names that tend to be given to oncology drugs after the FDA approved Altor BioScience’s Anktiva (nogapendekin alfa inbakicept-pmln plus Bacillus Calmette-Guérin) for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Although, a small number of eHCPs expressed their excitement about the launch

The three most shared stories from eHCPs discussing product launches in April were:

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • CREATION Pinpoint® listened to the discussions amongst online HCPs of pharmaceutical product launches and drug approvals between 1 April and 30 April 2024.  
  • The data included mentions of drug approvals by the FDA, EMA, NICE, and CHMP, as well as HCPs’ use of the phrase ‘drug approval’ in their tweets.
  • Between 1 and 30 April 2024, 1,432 online HCPs worldwide made 2,271 references to new pharmaceutical product launches and drug approvals. 

 

Share this article

Meet the Author

Alexandra Maria Chatziioannidou

As a Biological Sciences graduate, Alexandra is passionate about making an impact in the healthcare industry through creating actionable insights and telling stories with data from online healthcare conversations.

Alexandra loves spending quality time with friends and family, both in the UK and back home in Greece, on her holidays. She also enjoys exploring new places!

Suggested next


01.01.2021 | Article

Top 50 Pharma Tracker: COVID-19 makes up 84% of total conversation

Discover what healthcare professionals (HCPs) think about Top 50 Pharmaceutical companies

By Maria Aguirre

5 Steps To Make the Most Out Of Congress

29.05.2019 | Article

5 Steps To Make the Most Out Of Congress

5 Steps To Make the Most Out Of Congress

By Lara Meyer

View all articles >